 Stacey Bagby
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Xenograft Model Antitumor Assays | 23 | 2024 | 870 | 1.170 |
Why?
| | Colorectal Neoplasms | 12 | 2024 | 793 | 1.050 |
Why?
| | Melanoma | 9 | 2024 | 757 | 0.860 |
Why?
| | Antineoplastic Agents | 13 | 2020 | 2135 | 0.770 |
Why?
| | Mice, Nude | 16 | 2024 | 696 | 0.600 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2021 | 226 | 0.520 |
Why?
| | Protein Kinase Inhibitors | 7 | 2020 | 916 | 0.510 |
Why?
| | Drug Discovery | 1 | 2016 | 141 | 0.480 |
Why?
| | Azepines | 4 | 2024 | 90 | 0.480 |
Why?
| | Cell Line, Tumor | 21 | 2024 | 3414 | 0.470 |
Why?
| | Heterografts | 4 | 2021 | 138 | 0.460 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2024 | 202 | 0.450 |
Why?
| | Pyrimidines | 4 | 2020 | 471 | 0.440 |
Why?
| | Piperazines | 4 | 2021 | 350 | 0.440 |
Why?
| | Adrenocortical Carcinoma | 3 | 2020 | 65 | 0.430 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2024 | 1399 | 0.400 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2024 | 287 | 0.400 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2024 | 802 | 0.380 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2018 | 215 | 0.360 |
Why?
| | Quinoxalines | 3 | 2020 | 66 | 0.360 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2024 | 210 | 0.360 |
Why?
| | Dasatinib | 2 | 2024 | 54 | 0.360 |
Why?
| | Mice | 26 | 2024 | 17774 | 0.330 |
Why?
| | Cell Proliferation | 12 | 2024 | 2479 | 0.320 |
Why?
| | Disease Models, Animal | 7 | 2022 | 4284 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1688 | 0.320 |
Why?
| | Neoplasms | 5 | 2022 | 2661 | 0.300 |
Why?
| | Pancreatic Neoplasms | 3 | 2024 | 936 | 0.290 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2020 | 63 | 0.290 |
Why?
| | Tumor Microenvironment | 3 | 2022 | 674 | 0.280 |
Why?
| | Apoptosis | 13 | 2024 | 2554 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 805 | 0.260 |
Why?
| | Animals | 29 | 2024 | 36862 | 0.260 |
Why?
| | Anilides | 2 | 2018 | 73 | 0.250 |
Why?
| | Signal Transduction | 10 | 2024 | 5078 | 0.250 |
Why?
| | Pyridines | 3 | 2021 | 506 | 0.230 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 309 | 0.230 |
Why?
| | Bevacizumab | 1 | 2024 | 136 | 0.210 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 37 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 647 | 0.210 |
Why?
| | Mucous Membrane | 1 | 2024 | 125 | 0.210 |
Why?
| | Benzimidazoles | 1 | 2024 | 168 | 0.210 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2020 | 41 | 0.210 |
Why?
| | Deoxycytidine | 2 | 2024 | 178 | 0.210 |
Why?
| | Camptothecin | 3 | 2022 | 114 | 0.200 |
Why?
| | Immunotherapy | 3 | 2022 | 641 | 0.190 |
Why?
| | Wnt Signaling Pathway | 2 | 2024 | 192 | 0.180 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 209 | 0.180 |
Why?
| | Fluorouracil | 1 | 2022 | 210 | 0.180 |
Why?
| | beta Catenin | 2 | 2020 | 253 | 0.180 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 47 | 0.180 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2021 | 75 | 0.180 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 42 | 0.180 |
Why?
| | Transplantation, Heterologous | 2 | 2022 | 195 | 0.170 |
Why?
| | Momordica charantia | 1 | 2020 | 15 | 0.170 |
Why?
| | Aurora Kinase A | 2 | 2020 | 56 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 19 | 0.170 |
Why?
| | Humans | 38 | 2024 | 137294 | 0.160 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 176 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.160 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1274 | 0.160 |
Why?
| | Aniline Compounds | 1 | 2020 | 102 | 0.160 |
Why?
| | eIF-2 Kinase | 1 | 2019 | 31 | 0.160 |
Why?
| | Pyrimidinones | 2 | 2021 | 113 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 134 | 0.160 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 45 | 0.150 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 954 | 0.150 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
| | Pyridones | 2 | 2021 | 168 | 0.150 |
Why?
| | Plant Extracts | 1 | 2020 | 200 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 61 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 29 | 0.140 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.140 |
Why?
| | Drug Synergism | 2 | 2018 | 383 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 251 | 0.140 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 35 | 0.140 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 6 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 92 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 31 | 0.130 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2016 | 17 | 0.130 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 658 | 0.130 |
Why?
| | Cyclopentanes | 1 | 2016 | 20 | 0.130 |
Why?
| | Adenine | 1 | 2018 | 267 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2024 | 852 | 0.130 |
Why?
| | Corynebacterium | 1 | 2017 | 49 | 0.130 |
Why?
| | Sulfonamides | 1 | 2020 | 512 | 0.130 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 41 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 327 | 0.130 |
Why?
| | Tankyrases | 1 | 2016 | 15 | 0.130 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 44 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 281 | 0.120 |
Why?
| | Female | 22 | 2024 | 73052 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2018 | 412 | 0.120 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 73 | 0.120 |
Why?
| | Receptor, Notch1 | 1 | 2015 | 64 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2016 | 100 | 0.120 |
Why?
| | Pyrazoles | 1 | 2018 | 423 | 0.120 |
Why?
| | Gene Dosage | 1 | 2015 | 144 | 0.110 |
Why?
| | Phosphorylation | 4 | 2019 | 1759 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2024 | 2608 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 182 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 75 | 0.110 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 613 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 434 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2014 | 313 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 839 | 0.100 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 508 | 0.100 |
Why?
| | Gene Expression Profiling | 3 | 2024 | 1774 | 0.090 |
Why?
| | Cell Survival | 3 | 2019 | 1119 | 0.090 |
Why?
| | Mutation | 2 | 2018 | 3956 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2024 | 217 | 0.080 |
Why?
| | Cell Cycle | 3 | 2018 | 601 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2022 | 601 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2018 | 365 | 0.080 |
Why?
| | RNA, Small Interfering | 2 | 2024 | 622 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2243 | 0.080 |
Why?
| | Mice, Inbred BALB C | 2 | 2020 | 1269 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2024 | 530 | 0.060 |
Why?
| | HCT116 Cells | 2 | 2018 | 80 | 0.060 |
Why?
| | Aged | 6 | 2024 | 23851 | 0.060 |
Why?
| | Middle Aged | 7 | 2024 | 33310 | 0.060 |
Why?
| | Tumor Burden | 2 | 2018 | 309 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 226 | 0.060 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 301 | 0.060 |
Why?
| | Immunoblotting | 2 | 2015 | 307 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2018 | 436 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2024 | 168 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 112 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2024 | 190 | 0.050 |
Why?
| | Paclitaxel | 1 | 2024 | 227 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 66 | 0.050 |
Why?
| | Histone Deacetylase 1 | 1 | 2022 | 25 | 0.050 |
Why?
| | Doxorubicin | 1 | 2024 | 365 | 0.050 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 413 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.040 |
Why?
| | Acetylation | 1 | 2022 | 248 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 87 | 0.040 |
Why?
| | Aminopyridines | 1 | 2021 | 99 | 0.040 |
Why?
| | Male | 7 | 2024 | 67560 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 75 | 0.040 |
Why?
| | Membrane Proteins | 2 | 2018 | 1163 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2022 | 215 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 213 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 367 | 0.040 |
Why?
| | Adult | 5 | 2024 | 37724 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2020 | 94 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Indolizines | 1 | 2019 | 4 | 0.040 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 7 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2020 | 198 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 125 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 98 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 4026 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 792 | 0.040 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 43 | 0.040 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2018 | 7 | 0.040 |
Why?
| | GTP Phosphohydrolases | 1 | 2018 | 93 | 0.040 |
Why?
| | HT29 Cells | 1 | 2018 | 40 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 45 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1456 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1063 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 189 | 0.030 |
Why?
| | RNA | 1 | 2024 | 924 | 0.030 |
Why?
| | Piperidines | 1 | 2018 | 206 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 444 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 172 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 295 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
| | Histones | 1 | 2022 | 636 | 0.030 |
Why?
| | Axin Protein | 1 | 2016 | 19 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 102 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1692 | 0.030 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2016 | 23 | 0.030 |
Why?
| | Cetuximab | 1 | 2016 | 95 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 57 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 403 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 257 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 121 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 149 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 195 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 452 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 23 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 615 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 68 | 0.030 |
Why?
| | Diphenylamine | 1 | 2014 | 9 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 267 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 284 | 0.030 |
Why?
| | Neoplastic Stem Cells | 1 | 2018 | 400 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 95 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 218 | 0.030 |
Why?
| | RNA Interference | 1 | 2016 | 467 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3009 | 0.030 |
Why?
| | Benzamides | 1 | 2014 | 217 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 382 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 767 | 0.030 |
Why?
| | Transfection | 1 | 2016 | 947 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 537 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 844 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3202 | 0.020 |
Why?
| | Protein Binding | 1 | 2018 | 2225 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1734 | 0.020 |
Why?
| | Models, Biological | 1 | 2018 | 1773 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 10800 | 0.020 |
Why?
| | Transcriptome | 1 | 2015 | 972 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1431 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3568 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7607 | 0.010 |
Why?
|
|
Bagby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|